ClinicalTrials.gg
CompletedNCT01143090Switch ExtUpdated Jun 12, 2015Results posted

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

A Phase 3 interventional study of Lurasidone HCl in Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-12.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
20th of 39
149 · median 149
Started
2010
with 1 other
Phase 3
18 of 39
none open now
Registered
15th of 39
by date
Lead sponsor
23 of 39
Sumitomo Pharma America, Inc.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 20th largest by enrollment, is one of 2 that started in 2010, is one of 18 in phase 3, and was the 15th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has completed 6 weeks of treatment and all required assessments on the final study visit (Visit 8) of Study D1050289 (NCT01143077).

Exclusion criteria

Exclusion Criteria:

  • Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or damage to property.
  • Subject has a (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Open Label

    Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.

    Drug: Lurasidone HCl

Interventions

  • 40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Proportions of subjects with AEs, SAEs, and discontinuations due to AEs.

    Time frame: 6 months

Secondary outcomes

  1. Efficacy

    Long-term efficacy of lurasidone in subjects with schizophrenia or schizoaffective disorder who have completed Study D1050289

    Time frame: 6 months

07

Results

Posted Dec 17, 2012

Participant flow

FPI August 10, 2010-LPV November 28, 2011, locations were private health clinics, university hospitals, private research facilities.

Participant flow — Overall Study
MilestoneOpen Label
Started149
Completed98
Not completed51
Withdrew: Lack of efficacy2
Withdrew: Adverse event17
Withdrew: Lost to follow-up9
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject18
Withdrew: Non-compliance with study drug1
Withdrew: Failure to meet eligibility criteria1
Withdrew: Administrative1

Outcome measures

PrimaryAdverse Events

Proportions of subjects with AEs, SAEs, and discontinuations due to AEs.

Time frame:
6 months
Reported as:
Number · participants
Adverse Events
participantsLurasidone Overall
Any Treatment Emergent Adverse Event98
Any Severe Treatment Emergent Adverse Event10
Treatment Emergent AE Leading to Discontinuation16
SecondaryEfficacy

Long-term efficacy of lurasidone in subjects with schizophrenia or schizoaffective disorder who have completed Study D1050289

Time frame:
6 months

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label—8/148 (5.4%)47/148 (31.8%)
Most frequent serious events
Most frequent serious events
EventOpen Label
Schizoaffective DisorderPsychiatric disorders3/148
SchizophreniaPsychiatric disorders2/148
Suicidal IdeationPsychiatric disorders2/148
Bipolar I DisorderPsychiatric disorders1/148
Homicidal IdeationPsychiatric disorders1/148
ParanoiaPsychiatric disorders1/148
Most frequent other events
Most frequent other events
EventOpen Label
NauseaGastrointestinal disorders13/148
InsomniaPsychiatric disorders13/148
AkathisiaNervous system disorders12/148
AnxietyPsychiatric disorders9/148

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Open Label
<=18 years2
Between 18 and 65 years146
>=65 years0
Age, Continuous
Age, Continuous(years)Open Label
Mean42.8 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Open Label
Female55
Male93
Region of Enrollment
Region of Enrollment(participants)Open Label
United States148
08

Study locations

27 sites
  • K and S Professional Research Services
    Little Rock, Arkansas 72201, United States
  • Synergy Clinical Research of Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • Pacific Research Partners, LLC
    Oakland, California 94612, United States
  • California Clinical Trials
    Paramount, California 90723, United States
  • Pasadena Research Institute
    Pasadena, California 91107, United States
  • California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC
    Pico Rivera, California 90660, United States
  • California Neuropsychopharmacology Clinical Research Institute (CNRI)
    San Diego, California 92102, United States
  • University of California San Diego Medical Center
    San Diego, California 92103-8218, United States
  • Collaborative Neuroscience Network, South Bay
    Torrance, California 90502, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80204, United States
  • Comprehensive NeuroScience, Inc.
    Atlanta, Georgia 30328, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70601, United States
  • St. Charles Psychiatric Associates - Midwest Research
    St. Charles, Missouri 63301, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • The Zucker Hillside Hospital
    Glen Oaks, New York 11004, United States
  • Duke University Dept. of Psychiatry
    Durham, North Carolina 27710, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • CRI Worldwide - Kirkbride Center
    Philadelphia, Pennsylvania 19139, United States
  • FutureSearch Clinical Trials, LP
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • Pillar Clinical Research, LLC
    Dallas, Texas 75243, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Wharton Research Center
    Wharton, Texas 77488, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84132, United States
09

References and documents

Publications

  • Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014 Aug;19(4):330-9. doi: 10.1017/S109285291300093X. Epub 2013 Dec 16. PubMed 24330868 ↗
  • Awad G, Ng-Mak D, Rajagopalan K, Hsu J, Pikalov A, Loebel A. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. BMC Psychiatry. 2016 Jun 1;16:176. doi: 10.1186/s12888-016-0879-5. PubMed 27245981 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010 and a primary completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2010
First posted
Jun 14, 2010
Start
Aug 2010
Primary completionActual
Nov 2011
Results first posted
Dec 17, 2012
Last update
Jun 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01143090
Responsible party
Sponsor
First posted
Jun 14, 2010
Start date
Aug 2010
Primary completion
Nov 2011
Results posted
Dec 17, 2012
Last update
Jun 12, 2015

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion